FDMT (4D Molecular Therapeutics) Change In Inventory: $0.00 Mil (TTM As of Mar. 2026)

What is 4D Molecular Therapeutics Change In Inventory?

4D Molecular Therapeutics FDMT -4.50% 55 Change In Inventory is $0.00 Mil as of Mar. 2026. GuruFocus rates FDMT with a GF Score™ of 55/100 and a GF Value™ of $216.22 (Possible Value Trap). The stock has 7 warning signs investors should review.

4D Molecular Therapeutics's change in inventory for the quarter that ended in Mar. 2026 was $0.00 Mil. It means 4D Molecular Therapeutics's inventory stayed the same from Dec. 2025 to Mar. 2026 .

4D Molecular Therapeutics's change in inventory for the fiscal year that ended in Dec. 2025 was $0.00 Mil. It means 4D Molecular Therapeutics's inventory stayed the same from Dec. 2024 to Dec. 2025 .

4D Molecular Therapeutics's Total Inventories for the quarter that ended in Mar. 2026 was $0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. 4D Molecular Therapeutics's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.00.

4D Molecular Therapeutics (NAS:FDMT) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

4D Molecular Therapeutics's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	0	/	0	*	365 / 4
	=	N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

4D Molecular Therapeutics's Inventory Turnover for the quarter that ended in Mar. 2026 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=	N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

4D Molecular Therapeutics's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	3.047
	=	0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4D Molecular Therapeutics Change In Inventory Related Terms

4D Molecular Therapeutics Change In Inventory Historical Data

* Premium members only.

The historical data trend for 4D Molecular Therapeutics's Change In Inventory can be seen below:

4D Molecular Therapeutics Change In Inventory Chart

4D Molecular Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Change In Inventory

Get a 7-Day Free Trial

0.00

4D Molecular Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Change In Inventory	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

55GF Score

4D Molecular Therapeutics Inc FDMT

Change In Inventory is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

4D Molecular Therapeutics Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Frequently Asked Questions Learn more about Change In Inventory →

What does a Change In Inventory of $0.00 Mil mean?

4D Molecular Therapeutics (FDMT) has a Change In Inventory of $0.00 Mil as of Mar. 2026. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for 4D Molecular Therapeutics and its competitors.

Is 4D Molecular Therapeutics' Change In Inventory too high?

4D Molecular Therapeutics' current Change In Inventory is $0.00 Mil. Overall, 4D Molecular Therapeutics has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does 4D Molecular Therapeutics' Change In Inventory compare to TECX and ACHV?

4D Molecular Therapeutics' Change In Inventory of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Change In Inventory for a Biotechnology company?

A good Change In Inventory depends on the Biotechnology industry context. However, Change In Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Change In Inventory mean?

A high Change In Inventory can signal that a stock is expensive relative to its fundamentals. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for 4D Molecular Therapeutics and its competitors. 4D Molecular Therapeutics's current Change In Inventory is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is 4D Molecular Therapeutics stock overvalued right now?

Based on GuruFocus' analysis, 4D Molecular Therapeutics (FDMT) is currently considered Possible Value Trap. The stock's GF Value™ is $216.22, compared to a current price of $12.30 — trading 94.3% below its estimated fair value. The current Change In Inventory is $0.00 Mil. 4D Molecular Therapeutics' overall GF Score™ is 55/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Change In Inventory calculated?

Change In Inventory is calculated from a company's financial statements. For 4D Molecular Therapeutics (FDMT), the current Change In Inventory is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is 4D Molecular Therapeutics (FDMT) Overvalued in 2026?

Based on GuruFocus' analysis, 4D Molecular Therapeutics stock appears to be undervalued. The current stock price of $12.30 is trading 94.3% below its estimated GF Value™ of $216.22. GuruFocus considers 4D Molecular Therapeutics to be Possible Value Trap.

Key valuation signals for FDMT:

Change In Inventory: $0.00 Mil
GF Value™: $216.22 vs. price of $12.30 (94.3% below fair value)
GF Score™: 55/100 with 7 warning signs

No single metric tells the full story. See the FDMT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

4D Molecular Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies TECX ACHV STTK CRMD EIKN PRME BBOT FTH MNPR OMER VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Address 5858 Horton Street, Suite 455, Emeryville, CA, USA, 94608

Website https://www.4dmoleculartherapeutics.com

4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).

55GF Score

Get the complete analysis for FDMT

Change In Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.30

Price

$216.22

GF Value

View FDMT Analysis

See Change In Inventory data for all stocks →